alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › aggregates

aggregates

5 studies tagged aggregates, dated 2011-10-14 to 2026-04-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain 2026-04-01
  2. Relationship between efficacy and preferential targeting of soluble Aβ aggregates 2025-10-01
  3. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease 2025-04-01

Studies

5 studies carry this tag.

Date range

2011 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 2
  • Alzheimer's & dementia (New York, N. Y.) 1
  • Biomacromolecules 1
  • bioRxiv 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-04-01 Treatments

    Lecanemab's binding target is similar to other antibodies'.

  2. Relationship between efficacy and preferential targeting of soluble Aβ aggregates

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-10-01 Treatments

    These results suggest that selectivity for soluble toxic oligomers correlates with clinical efficacy, potentially attenuating monomer competition and amyloid-related imaging abnormalities (ARIA).

  3. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-04-01 Treatments

    These findings provide an explanation for the success of Lecanemab in clinical trials and suggests that Lecanemab will be more effective when used in early-stage AD.

  4. Relationship Between Therapeutic Activity and Preferential Targeting of Toxic Soluble Aggregates by Amyloid-Beta-Directed Antibodies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2024-04-25 Treatments

    Overall, these results suggest that selectivity for soluble toxic Aβ oligomers may be a driver of clinical efficacy, with a potentially reduced risk of ARIA if engagement with plaque is minimized.

  5. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biomacromolecules 2011-10-14 Treatments

    Dendrimers have been proved to interact with amyloids, although most of dendrimers assayed in amyloidogenic systems are toxic to cells.

All topic tags with their study counts